LCZ 696, administered during doxorubicin, trastuzumab or pertuzumab treatment, prevents cardiotoxicity in our in vitro model
Nicola Maurea(Cancer Institute (WIA)), Claudia De Lorenzo(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Anna Di Rienzo(University of Chicago), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giovanna Piscopo(University of Cagliari), Carlo Maurea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giorgia Sorrentino(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmela Coppola, Rolando Paciello(CEINGE Biotecnologie Avanzate Franco Salvatore (Italy)), R. Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Piera Maiolino
Cited by 4
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282
Getting genetic ancestry right for science and society
|Science|2022|226